Humans control viral infections using two unique immune system programs, the fast-acting innate immune system and the slower acting adaptive (antibody) immune system that can be induced by vaccines. Substantial research efforts have focused on the development of vaccine-based coronavirus control strategies. Recently, however, it has been recognized that the fast-acting innate immune system is the major coronavirus immune response in children and may account for the lower morbidity and mortality in children versus adults1.
Spartina Biotechnologies’ SIREN™ technology directly activates the innate immune response while simultaneously blocking viral replication through the targeted and effective delivery of RNA interference (RNAi) molecules to virus infected cells.
Significantly, SIREN technology addresses the major challenges that have impeded the application of RNA interference (RNAi) technology in the past including, optimization of RNAi molecular structures for targeted viral gene silencing, stable delivery of RNAi molecules to the patient in an effective dose, and specific targeting of RNAi molecules to virus infected cells.
Our solution is designed to pack a one-two punch for the control of SARS-CoV-2 infections. In short, we simultaneously block viral replication and activate the innate immune system to attack the virus. This will allow the patient to recover faster, with fewer long-term impacts, and be protected from future infections. Furthermore, unlike traditional vaccines, our SIREN technology can be rapidly modified for use against emerging coronavirus variants (mutants) or other viruses.
1. Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci Transl Med 2020; 5487(September):1–17. Available from: http://www.ncbi.nlm.nih.gov/
The following videos are provided to help you understand RNAi:
1. RNA interference by Nature – RNAi at the molecular level
2. NOVA Science Now – RNAi for the novice.